Neutral/Negative Catalysts
- Regulatory setback: FDA Complete Response Letter for Saphnelo subcutaneous BLA adds uncertainty/timeline risk (additional information requested; decision expected 1H 2026).
- Technical timing: RSI ~92 indicates an overheated tape—entry today is statistically more vulnerable to short-term mean reversion.
- Near-term event risk: Earnings on 2026-02-10 pre-market can trigger a sharp repricing either direction.
- Not unanimous on the Street: Deutsche Bank maintains a Sell rating despite raising its price target; Goldman removed AZN from its European Conviction List.
